Multicenter single arm study of Bezlotoxumab for prevention of recurrent Clostridium difficile infection
Phase of Trial: Phase IV
Latest Information Update: 08 Nov 2018
Price : $35 *
At a glance
- Drugs Bezlotoxumab (Primary)
- Indications Clostridium difficile infections
- Focus Therapeutic Use
- 08 Nov 2018 New trial record
- 07 Oct 2018 Results (n=29) assessing Bezlotoxumab treatment for the recurrence of Clostridium difficile Infection, presented at the IDWeek 2018.
- 07 Oct 2018 Results assessing risk factors for prevention of recurrent clostridium difficle infection, presented at the IDWeek 2018.